Radiation-Activatable Platinum Complex for Deep Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using platinum-based chemodrugs face challenges such as low bioavailability, severe side effects, poor stability, and inherent or acquired resistance, while photoactivatable Pt(IV) prodrugs are limited by shallow light penetration and antioxidant defenses in cancer cells, necessitating alternative therapies with improved efficacy and reduced side effects.
Innovation Solution
A radiation-activatable platinum complex with a specific structure that generates reactive oxygen species and reduces to a cytotoxic form upon exposure to radiation, enhancing cytotoxicity and overcoming resistance in cancer cells, including those resistant to cisplatin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If photoactivatable Pt(IV) prodrugs are used, then non-invasiveness and controllability are improved, but light penetration depth is limited reducing efficacy against deep tumors
Solution Approach 1:
The patent changes the activation parameter from optical (light) to acoustic (ultrasound) radiation. The Pt(IV) complex is designed to be activated by ultrasound-induced sonodynamic therapy, which enables deep tissue penetration while maintaining non-invasive and controllable activation. This parameter change resolves the contradiction by replacing light activation with ultrasound activation.
2Reliability
If single-mode ROS generation therapy is used, then tumor cell apoptosis is achieved, but antioxidant defence mechanism of cancer cells counters the effect
Solution Approach 1:
The patent merges multiple therapeutic mechanisms into a single Pt(IV) complex: (1) ROS generation through sonodynamic activation, (2) cytotoxic platinum(II) species release through reductive elimination, and (3) DNA binding capability. This combination overcomes the limitation of single-mode ROS therapy by providing dual mechanisms that work synergistically to counteract cancer cell antioxidant defenses.
Solution Approach 2:
The Pt(IV) complex functions as a composite therapeutic agent combining sonosensitizer properties, platinum-based chemotherapeutic properties, and radiation-responsive characteristics. This composite material approach enables multi-modal therapy within a single molecule, improving reliability while overcoming cellular resistance mechanisms.
3Reliability
If platinum-based chemodrugs are used, then antitumor activity is achieved, but severe side effects and poor stability occur
Solution Approach 1:
The Pt(IV) complex serves as a prodrug that is stable during administration and circulation, then undergoes activation only after reaching the target tissue through ultrasound irradiation. This preliminary stabilization followed by controlled activation reduces side effects while maintaining antitumor activity, as the active cytotoxic species are generated only at the treatment site.
Solution Approach 2:
The Pt(IV) prodrug acts as an intermediary form that transports the platinum-based therapeutic agent to the tumor site in a stable, low-toxicity state, then converts to the active cytotoxic Pt(II) species upon ultrasound activation. This intermediary approach reduces systemic side effects while preserving the potent antitumor activity of platinum compounds.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platinum complex remains stable until activated by radiation, achieving enhanced cytotoxicity up to six times, effectively targeting and reducing cancer cell proliferation, including cisplatin-resistant cells, with minimal side effects and improved tissue penetration.
Implementation Method 1
when the sonosensitizer is exposed to US with a specific frequency range in conjunction with molecular oxygen, reactive oxygen species (ROS) will be generated and causes tumor cell apoptosis and/or necrosis
Implementation Method 2
The present invention also relates to the preparation of the complex as well as the use of it in treating a disease, in particular, but not exclusive to a cancer
Data Source
AI summary
A platinum complex having a structure of Formula (I) particularly of Formula (A) such as Formula (III) or Formula (IIIa). A pharmaceutical composition includes the platinum complex of the present invention and a pharmaceutically acceptable carrier. A method of treating a target tissue includes administering to a patient in need thereof a platinum complex of the present invention and administering to the target tissue radiation in an amount and of a frequency effective to activate the compound. The platinum complex of the present invention can be used in preparation of a medicament for treating the target tissue by sonodynamic therapy, photodynamic therapy, chemotherapy and/or a combination thereof.